Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
Anant Madabhushi, CCIPD Director. Credit: Case Western Reserve University

New research at Case Western Reserve University could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Once a lumpectomy of tissue reveals this pre-, most women have surgery to remove the remainder of the affected tissue and some are given as well, said Anant Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at the Case School of Engineering.

"Current testing places patients in high risk, low risk and indeterminate risk—but then treats those 'indeterminates' with radiation, anyway," said Madabhushi, whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) conducted the new research. "They err on the side of caution, but we're saying that it appears that it should go the other way—the middle should be classified with the lower risk.

"In short, we're probably over-treating patients," Madabhushi continued. "That goes against prevailing wisdom, but that's what our analysis is finding."

The most common breast cancer

Stage 0 is the most and known clinically as in situ (DCIS), indicating that the cancer cell growth starts in the milk ducts.

About 60,000 cases of DCIS are diagnosed in the United States each year, accounting for about one of every five new breast cancer cases, according to the American Cancer Society. People with a type of breast cancer that has not spread beyond the breast tissue live at least five years after diagnosis, according to the cancer society.

Lead researcher Haojia Li, a in the CCIPD, used a computer program analyze the spatial architecture, texture and orientation of the individual cells and nuclei from scanned and digitized lumpectomy tissue samples from 62 DCIS patients.

The result: Both the size and orientation of the tumors characterized as "indeterminate" were actually much closer to those confirmed as low risk for recurrence by an expensive genetic test called Oncotype DX.

Li then validated the features that distinguished the low and high risk Oncotype groups in being able to predict the likelihood of progression from DCIS to invasive ductal carcinoma in an independent set of 30 patients.

"This could be a tool for determining who really needs the radiation, or who needs the gene test, which is also very expensive," she said.

The research led by Li was published Oct. 17 in the journal Breast Cancer Research.

Madabhushi established the CCIPD at Case Western Reserve in 2012. The lab now includes nearly 60 researchers. The lab has become a global leader in the detection, diagnosis and characterization of various cancers and other diseases, including breast cancer, by meshing medical imaging, machine learning and artificial intelligence (AI).

Some of the lab's most recent work, in collaboration with New York University and Yale University, has used AI to predict which lung patients would benefit from adjuvant chemotherapy based on tissue slide images.

That advancement was named by Prevention Magazine as one of the top 10 medical breakthroughs of 2018.


Explore further

Sentinel lymph node biopsy has no benefits for stage zero breast cancer

More information: Haojia Li et al. Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings, Breast Cancer Research (2019). DOI: 10.1186/s13058-019-1200-6
Journal information: Breast Cancer Research

Citation: Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer (2019, October 29) retrieved 12 December 2019 from https://medicalxpress.com/news/2019-10-breast-cancer-ai-pre-malignant-lesions.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments